Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs.
Heron Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$12.59|
|52 Week High||US$10.10|
|52 Week Low||US$22.40|
|1 Month Change||8.16%|
|3 Month Change||-24.25%|
|1 Year Change||-13.83%|
|3 Year Change||-60.22%|
|5 Year Change||-26.93%|
|Change since IPO||-97.26%|
Recent News & Updates
|HRTX||US Biotechs||US Market|
Return vs Industry: HRTX underperformed the US Biotechs industry which returned 31% over the past year.
Return vs Market: HRTX underperformed the US Market which returned 37.5% over the past year.
Stable Share Price: HRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: HRTX's weekly volatility (5%) has been stable over the past year.
About the Company
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company’s product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Heron Therapeutics Fundamentals Summary
|HRTX fundamental statistics|
Is HRTX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HRTX income statement (TTM)|
|Cost of Revenue||US$206.08m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-2.30|
|Net Profit Margin||-281.99%|
How did HRTX perform over the long term?See historical performance and comparison
Is Heron Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HRTX ($12.59) is trading below our estimate of fair value ($91.79)
Significantly Below Fair Value: HRTX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: HRTX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: HRTX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate HRTX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: HRTX is overvalued based on its PB Ratio (8x) compared to the US Biotechs industry average (3.3x).
How is Heron Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HRTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: HRTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: HRTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: HRTX's revenue (40.4% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: HRTX's revenue (40.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if HRTX's Return on Equity is forecast to be high in 3 years time
How has Heron Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HRTX is currently unprofitable.
Growing Profit Margin: HRTX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: HRTX is unprofitable, and losses have increased over the past 5 years at a rate of 6.6% per year.
Accelerating Growth: Unable to compare HRTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HRTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: HRTX has a negative Return on Equity (-146.23%), as it is currently unprofitable.
How is Heron Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: HRTX's short term assets ($366.8M) exceed its short term liabilities ($82.1M).
Long Term Liabilities: HRTX's short term assets ($366.8M) exceed its long term liabilities ($162.0M).
Debt to Equity History and Analysis
Debt Level: HRTX's debt to equity ratio (93%) is considered high.
Reducing Debt: HRTX's debt to equity ratio has increased from 5.4% to 93% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HRTX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if HRTX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Heron Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HRTX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HRTX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Barry Quart (64 yo)
Dr. Barry D. Quart, Pharm D., has been the Chief Executive Officer of Heron Therapeutics, Inc. since 2013 and has been its Director since 2013. Dr. Quart has been Chairman of Heron Therapeutics, Inc. since...
CEO Compensation Analysis
Compensation vs Market: Barry's total compensation ($USD5.35M) is above average for companies of similar size in the US market ($USD3.67M).
Compensation vs Earnings: Barry's compensation has been consistent with company performance over the past year.
Experienced Management: HRTX's management team is considered experienced (4.7 years average tenure).
Experienced Board: HRTX's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.
Heron Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Heron Therapeutics, Inc.
- Ticker: HRTX
- Exchange: NasdaqCM
- Founded: 1983
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.283b
- Shares outstanding: 101.91m
- Website: https://www.herontx.com
Number of Employees
- Heron Therapeutics, Inc.
- 4242 Campus Point Court
- Suite 200
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/25 02:10|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.